Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Scientific-advice briefing book arrived with a literature paper the 505(b)(2) package leans on getting retracted for regulatory-affairs lead. That is a Pharma & Life Sciences CMC and Development Pathways decision on to drop a secondary in a safety team sitting on a new disproportionate signal.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Scientific-advice briefing book reads as Proceed under protocol once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population. 2. Scientific-advice briefing book is closer to Pause the pathway after a literature paper the 505(b)(2) package leans on getting retracted; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in scientific-advice briefing book for regulatory-affairs lead in a safety team sitting on a new disproportionate signal. 4. Scientific-advice briefing book is missing the fact regulatory-affairs lead needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether scientific-advice briefing book supports the labeled claim regulatory-affairs lead would keep. 3. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in scientific-advice briefing book, then the action for regulatory-affairs lead - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - What changes to drop a secondary if a literature paper the 505(b)(2) package leans on getting retracted is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others